Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;27(2):202-7.
doi: 10.1007/s00380-011-0141-5. Epub 2011 Apr 20.

Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway

Affiliations

Urocortin-induced cardiomyocytes hypertrophy is associated with regulation of the GSK-3β pathway

Damien Gruson et al. Heart Vessels. 2012 Mar.

Abstract

Urocortin-1 (UCN), a member of the corticotropin-releasing factor, is a cardioprotective peptide, and is also involved in cardiac hypertrophy. The involvement of GSK-3β, a pivotal kinase in cardiac hypertrophy, in response to UCN is not yet documented. Cardiomyocytes from adult rats were stimulated for 48 h with UCN. Cell size, protein, and DNA contents were determined. Phosphorylated and total forms GSK-3β and the total amount of β-catenin were quantified by Western immunoblots. The effects of astressin, a UCN competitive receptor antagonist, were also evaluated. UCN increased cell size and the protein-to-DNA ratio, in accordance with a hypertrophic response. This effect was associated with increased phosphorylation of GSK-3β and marked accumulation of β-catenin, a downstream element to GSK-3β. All these effects were prevented by astressin and LY294002, an inhibitor of the phosphatidyl-inositol-3-kinase. UCN-induced cardiomyocytes hypertrophy is associated with regulation of GSK-3β, a pivotal kinase involved in cardiac hypertrophy, in a PI3K-dependent manner. Furthermore, the pharmacological blockade of UCN receptors was able to prevent UCN-induced hypertrophy, which leads to inhibition of the Akt/GSK-3β pathway.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Invest. 2005 Mar;115(3):527-37 - PubMed
    1. Nat Rev Drug Discov. 2004 Jun;3(6):479-87 - PubMed
    1. Heart Vessels. 2010 Sep;25(5):438-43 - PubMed
    1. Peptides. 2005 Dec;26(12):2473-81 - PubMed
    1. Biochem J. 2001 Oct 1;359(Pt 1):119-27 - PubMed

MeSH terms

LinkOut - more resources